法国在 COVID-19 大流行期间和为 COVID-19 疫苗全国药物流行病学监测进行的真实研究的贡献。
Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines.
机构信息
EPI-PHARE, Epidemiology of Health Products (French National Agency for Medicines and Health Products Safety, and French National Health Insurance), Saint-Denis cedex, France; University of Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-Infective Evasion and Pharmaco-epidemiology, CESP (Center for Research in Epidemiology and Population Health), 78180 Montigny le Bretonneux, France.
EPI-PHARE, Epidemiology of Health Products (French National Agency for Medicines and Health Products Safety, and French National Health Insurance), Saint-Denis cedex, France.
出版信息
Therapie. 2023 Sep-Oct;78(5):553-557. doi: 10.1016/j.therap.2022.12.013. Epub 2023 Jan 20.
During the COVID-19 pandemic, EPI-PHARE, a scientific group in pharmaco-epidemiology created by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French National Health Insurance (Cnam), has reoriented its work program to enlighten health authorities in this health crisis. By exploiting massive and complex data of the French Health Data System (SNDS) from the beginning of the first lockdown in France in March 2020, we were able to publish numerous results on the use, benefits and risks of medicines, on the risk factors of COVID-19 before and after vaccination, and on the benefits and risks of COVID-19 vaccines. Our results were widely taken into account by the French health authorities and allowed them to take informed decision in this pandemic situation in order to ensure the health of the population.
在 COVID-19 大流行期间，由法国国家药品和保健产品安全局（ANSM）和法国国家健康保险（Cnam）创建的药物流行病学科学小组 EPI-PHARE 重新调整了其工作计划，为这场卫生危机中的卫生当局提供指导。通过利用法国健康数据系统（SNDS）从 2020 年 3 月法国首次封锁开始的大量复杂数据，我们能够就药品的使用、效益和风险、疫苗接种前后 COVID-19 的风险因素以及 COVID-19 疫苗的效益和风险发表众多研究成果。我们的研究结果得到了法国卫生当局的广泛关注，并使他们能够在这种大流行情况下做出明智的决策，以确保民众的健康。
Zotero 插件